Get started
Author

Leila Russo

Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab
2021 · Otto Metzger Filho, Giuseppe Viale, et al. · Cancer Discovery · 256
PDF
Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study
2014 · Ann E. McCullough, Patrizia Dell’Orto, et al. · Breast Cancer Research and Treatment · 66
Gastric metastases originating from occult breast lobular carcinoma: diagnostic and therapeutic problems
2008 · Antonio Ciulla, Gioacchino Castronovo, et al. · World Journal of Surgical Oncology · 50
PDF
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT
2024 · Paolo Tarantino, Nabihah Tayob, et al. · Journal of Clinical Oncology · 48
PDF
Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials
2015 · SOFT and TEXT Investigators and International Breast Cancer Study Group, Meredith M. Regan, et al. · Breast Cancer Research and Treatment · 47
Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes
2019 · Giuseppe Viale, Amy E. Hanlon Newell, et al. · Breast Cancer Research and Treatment · 44
PDF
Adjuvant therapies for special types of breast cancer
2011 · Marco Colleoni, Leila Russo, et al. · The Breast · 33
PDF
Highly reproducible results of breast cancer biomarkers when analysed in accordance with national guidelines – a Swedish survey with central re-assessment
2015 · Maria Ekholm, Dorthe Grabau, et al. · Acta Oncologica · 27
PDF
Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer
2016 · Giuseppe Viale, Leen Slaets, et al. · Breast Cancer Research and Treatment · 22
PDF
Immunohistochemical Performance of Estrogen and Progesterone Receptor Antibodies on the Dako Omnis Staining Platform: Evaluation in Multicenter Studies
2015 · David Hicks, Patrizia Dell’Orto, et al. · Applied immunohistochemistry & molecular morphology · 13
Abstract PS09-02: Event-free Survival by Residual Cancer Burden (RCB) and Intratumor HER2 Heterogeneity after Neoadjuvant T-DM1 and Pertuzumab for Early-stage HER2-positive Breast Cancer
2024 · Otto Metzger, Se Eun Kim, et al. · Cancer Research · 4
The role of sentinel lymph-node biopsy (SLNB) in the treatment of breast cancer.
2006 · Antonio Marrazzo, Pietra Taormina, et al. · PubMed · 4
Abstract P4-11-08: Pathological assessment of discordant cases for molecular (BluePrint and MammaPrint) vs clinical subtypes for breast cancer, among 6,694 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial
2015 · Giuseppe Viale, Leen Slaets, et al. · Cancer Research · 3
Comparison of molecular (BluePrint+MammaPrint) and pathological subtypes for breast cancer among the first 800 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial.
2012 · Giuseppe Viale, Leen Slaets, et al. · Journal of Clinical Oncology · 2
Comparison of molecular (BluePrint and MammaPrint) and pathological subtypes for breast cancer among the first 800 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial.
2012 · Giuseppe Viale, Leen Slaets, et al. · Journal of Clinical Oncology · 1
Data from Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab
2023 · Otto Metzger Filho, Giuseppe Viale, et al.
Data from Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab
2023 · Otto Metzger Filho, Giuseppe Viale, et al.
Supplementary Table S1 from Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab
2023 · Otto Metzger Filho, Giuseppe Viale, et al.
Supplementary Fig. S3 from Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab
2023 · Otto Metzger Filho, Giuseppe Viale, et al.
PDF
Supplementary Fig. S2 from Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab
2023 · Otto Metzger Filho, Giuseppe Viale, et al.
PDF
Supplementary Fig. S4 from Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab
2023 · Otto Metzger Filho, Giuseppe Viale, et al.
PDF
Supplementary Table S2 from Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab
2023 · Otto Metzger Filho, Giuseppe Viale, et al.
Supplementary Table S2 from Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab
2023 · Otto Metzger Filho, Giuseppe Viale, et al.
Supplementary Fig. S1 from Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab
2023 · Otto Metzger Filho, Giuseppe Viale, et al.
PDF
Supplementary Fig. S1 from Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab
2023 · Otto Metzger Filho, Giuseppe Viale, et al.
Works count: 39
Citation count: 620
H-index: 10
I10-index: 10
Year
Topic
Type